- Report
- February 2024
- 70 Pages
Russia
From €4208EUR$4,750USD£3,641GBP
- Report
- February 2024
- 70 Pages
Australia
From €4208EUR$4,750USD£3,641GBP
- Report
- February 2024
- 70 Pages
China
From €4208EUR$4,750USD£3,641GBP
- Report
- February 2024
- 70 Pages
Japan
From €4208EUR$4,750USD£3,641GBP
- Report
- February 2024
- 70 Pages
Japan
From €4208EUR$4,750USD£3,641GBP
- Report
- August 2023
- 70 Pages
Africa, Middle East
From €4208EUR$4,750USD£3,641GBP
- Report
- August 2023
- 70 Pages
Spain
From €4208EUR$4,750USD£3,641GBP
- Report
- August 2023
- 70 Pages
South Korea
From €4208EUR$4,750USD£3,641GBP
- Report
- April 2023
- 110 Pages
Global
From €4208EUR$4,750USD£3,641GBP
- Report
- October 2022
- 70 Pages
Africa
From €4208EUR$4,750USD£3,641GBP
- Report
- March 2019
- 90 Pages
Europe
From €4208EUR$4,750USD£3,641GBP
- Report
- July 2024
- 70 Pages
Global
From €4208EUR$4,750USD£3,641GBP
- Report
- February 2024
- 150 Pages
Global
From €4208EUR$4,750USD£3,641GBP
- Report
- February 2024
- 85 Pages
North America
From €4208EUR$4,750USD£3,641GBP
- Report
- February 2024
- 181 Pages
Europe
From €4208EUR$4,750USD£3,641GBP
- Report
- August 2023
- 90 Pages
Global
From €4208EUR$4,750USD£3,641GBP
- Report
- August 2023
- 150 Pages
North America
From €4208EUR$4,750USD£3,641GBP
- Report
- May 2024
- 200 Pages
Global
From €3677EUR$4,150USD£3,181GBP
- Report
- June 2024
- 140 Pages
Asia Pacific
From €3428EUR$3,869USD£2,966GBP
- Report
- June 2024
- 140 Pages
Latin America
From €3428EUR$3,869USD£2,966GBP

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used as an anti-obesity drug. It is a long-acting analogue of human GLP-1, a hormone that is released in response to food intake. Liraglutide works by stimulating the release of insulin and suppressing appetite. It is typically prescribed as an adjunct to diet and exercise for the treatment of obesity. It is also used to treat type 2 diabetes.
Liraglutide is available in both injectable and oral formulations. The injectable form is administered subcutaneously once daily, while the oral form is taken once daily with food. Common side effects of liraglutide include nausea, vomiting, diarrhea, and abdominal pain.
Several companies are involved in the liraglutide market, including Novo Nordisk, Eli Lilly, Sanofi, and Merck. Show Less Read more